Estimates of Seasonal Influenza Burden That Could Be Averted by Improved Influenza Vaccines in the Australian Population Aged Under 65 Years, 2015–2019

Abstract

BackgroundThe interpretation of relative vaccine effectiveness (rVE) of improved influenza vaccines is complex. Estimation of burden averted is useful to contextualise their potential impact across different seasons. For the population aged under 65 years in Australia, this study estimated the additional morbidity and mortality that could be averted using improved influenza vaccines.MethodsWe used observed, season‐specific (2015–2019) influenza notification and influenza‐coded hospitalisation frequencies and published modelled estimates of influenza‐associated hospitalisations and deaths that occurred under the prevailing influenza vaccination coverage scenario. After back‐calculating to the estimated burden in the population without vaccination, we applied published standard influenza vaccine effectiveness and coverage estimates to calculate the burden potentially averted by standard and improved influenza vaccines. A plausible range of rVE values were used, assuming 50% coverage.ResultsThe percentage point difference in absolute vaccine effectiveness (VE) of an improved vaccine compared to a standard vaccine is directly proportional to its rVE and inversely proportional to the effectiveness of the standard vaccine. The incremental burden averted by an improved vaccine is a function of both its difference in absolute VE and the severity of the influenza season. Assuming an rVE of 15% with 50% coverage, the improved vaccine was estimated to additionally avert 1517 to 12,641 influenza notifications, 287 to 1311 influenza‐coded hospitalisations and 9 to 33 modelled all‐cause influenza deaths per year compared to the standard vaccine.ConclusionsImproved vaccines can have substantial clinical and population impact, particularly when the effectiveness of standard vaccines is low, and burden is high.